In neonatal DMD ΔEx50 mice and young DMD ΔEx50 dogs, the systemic administration of SpCas9 components results in widespread dystrophin restoration throughout body muscles, improves the expression of DGC complex, repairs muscle structure and histology, and enhances muscle strength [138,139,140]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.